Select Page

Major factor driving growth of the enteral syringe market is increasing prevalence of chronic diseases such as cancer, which often results in hospital admissions in late stage of the disease. These patients are unable to ingest any kind of food and medicines, therefore, enteral syringes are preferred in such situations.

According to a report by International Agency for Research on Cancer, titled GLOBOSCAN, September 2018, around 18.1 million new cancer cases and 9.6 million cancer deaths were recorded in 2018, worldwide. Moreover, same source mentions that, one out of every five men and one out of every six women worldwide suffer from cancer during their lifetime and one out of every eight men and one out of every 11 women die from the disease. The total number of people surviving within 5 years of a cancer diagnosis, called the 5-year prevalence, is around 43.8 million, worldwide.

Request Sample Copy of this Research Report @

Key players in the market are focused on launching ENFit design-based enteral syringes as per new guidelines initiated by Global Enteral Device Supplier Association (GEDSA) and other key stakeholder under Stay Connected in 2015. ENFit designs help to reduce incidences of misconnections incidence, thereby offering enhanced safety while using enteral syringes. In February 2017, Baxter International Inc. launched new enteral ENFit syringe and accessory line for patients requiring tube feeding. Baxter’s new enteral ENFit syringes are designed to improve patient safety during enteral nutrition (EN) therapy by preventing misconnections or wrong-route administration that can cause severe patient injury.

Increasing number of neonatal admissions to NICU, high prevalence of chronic diseases, and increasing geriatric population worldwide are expected to propel growth of the global enteral syringe market during the forecast period. According to World Health Organization’s report: Born Too Soon: The Global Action Report on Preterm Birth, published in 2012, 1.1 million premature infants die, annually and however, 75 % could survive with simple treatments such as feeding them nutrition and medications in time. According to same source, around 15 million infants are born annually, of which more than one in every 10 infants are born prematurely.

Purchase Copy of This Business Research Report:

Furthermore, merger and acquisition strategies adopted by key market players are also expected to boost the market growth. For instance, in March 2017, GBUK Group Ltd announced acquisition of Intervene Group Ltd that resulted in additions of Intervene’s enteral devices products such as Enteralok, Surety, ENFit Dash3, NRFit Dash6, and BP cuff product ranges to the GBUK Group portfolio.

For instance, in 2016, NeoMed and Medtronic received the U.S FDA 510(k) clearance for low dose tip ENFit syringes. NeoMed has offered royalty-free access of its design to all syringe manufacturers. Therefore, several manufacturers can implement this design standard to promote safe use of these devices, which in turn is expected to increase adoption of enteral syringes.

Key players operating in the global enteral syringe market include, B. Braun Melsungen AG, GBUK Enteral Ltd., Thermo Fischer, Inc., Koninklijke Philips N.V., Miktell Ltd., Baxter International, Inc., Cardinal Health, Inc., Terumo Corporation, Kentec Medical, Inc., Vygon S.A., and others.

Read Press Release on Immuno Oncology Assays Market: